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Case Report
Introduction
Status epilepticus (SE) is defined by the International League 
against Epilepsy (ILAE) as a condition resulting either from 
the failure of the mechanisms responsible for seizure termi-
nation or from the initiation of mechanisms, which (after 
time point t
1
) lead to abnormally prolonged seizures and 
which (after time point t
2
) result in long-term consequences 
including neuronal death, neuronal injury, and alteration of 
neuronal networks, depending on the duration and seizures 
type.1,2 A classification system for SE was recently proposed 
by the ILAE based on 4 criteria (axes): semiology (Table 1), 
etiology, age, and electroencephalography (EEG) correlates.1 
The following information must be included in describing 
the EEG in SE: (1) spatial distribution: generalized or bisyn-
chronous, lateralized, bilateral independent, multifocal); (2) 
name of pattern: periodic discharges, rhythmic delta activity, 
or spike-and-wave/sharp-and-wave plus subtypes: (3) mor-
phology: sharpness, number of phases (eg, triphasic), abso-
lute and relative amplitude, polarity; (4) temporal features: 
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Abstract
Refractory seizures or status epilepticus (RS/SE) continues to be a challenge in the inpatient setting. Failure to abort 
a seizure with antiepileptic drugs (AEDs) may lead to intubation and treatment with general anesthesia exposing 
patients to complications, extending hospitalization, and increasing the cost of care. Studies have shown a key role of 
inflammatory mediators in seizure generation and termination. We describe 4 patients with RS/SE that was aborted when 
dexamethasone was added to conventional AEDs: a 61-year-old female with temporal lobe epilepsy who presented with 
delirium, nonconvulsive status epilepticus, and oculomyoclonic status; a 56-year-old female with history of traumatic 
left frontal lobe hemorrhage who developed right face and hand epilepsia partialis continua followed by refractory 
focal clonic seizures; a 51-year-old male with history of traumatic intracranial hemorrhage who exhibited left-sided 
epilepsia partialis continua; and a 75-year-old female with history of breast cancer who manifested nonconvulsive 
status epilepticus and refractory focal clonic seizures. All patients continued experiencing RS/SE despite first- and 
second-line therapy, and one patient continued to experience RS/SE despite third-line therapy. Failure to abort RS/SE 
with conventional therapy motivated us to administer intravenous dexamethasone. A 10-mg load was given (except 
in one patient) followed by 4.0- 5.2 mg q6h. All clinical and electrographic seizures stopped 3-4 days after starting 
dexamethasone. When dexamethasone was discontinued 1-3 days after seizures stopped, all patients remained seizure-
free on 2-3 AEDs. The cessation of RS/SE when dexamethasone was added to conventional antiseizure therapy suggests 
that inflammatory processes are involved in the pathogenesis of RS/SE.
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onset (sudden vs gradual), prevalence, frequency, duration, 
daily pattern, dynamics (evolving, fluctuating, or static); (5) 
modulation: stimulus-induced versus spontaneous; and (6) 
effects of interventions, such as antiepileptic drug (AED) 
administration.1,3
Convulsive SE (CSE; A.1.a. in Table 1) is character-
ized by prolonged (>5 minutes) convulsions, that is, epi-
sodes of excessive abnormal muscle contractions, usually 
bilateral, which may be sustained or interrupted.1,4 The 
best time point estimates for CSE are: t
1
 = 5 minutes, 
t
2
 = 30 minutes.1 Nonconvulsive SE (NCSE; SE.B cate-
gory in Table 1) includes all SE subtypes without promi-
nent motor manifestations (Table1). The best time point 
estimates for focal NCSE with impaired consciousness 
(B.2.b.c in Table 1) are: t
1
 = 10 minutes, t
2
 > 60 minutes.1 
In this article, we will simply refer to the B.2.b.c subtype 
of NCSE as NCSE. Refractory status epilepticus (RSE) 
has no universally accepted definition. Some definitions 
specify a minimum number of AEDs to which SE fails to 
respond (eg, 2 or 3) or a minimum time over which SE 
persists despite adequate treatment (eg, 1 or 2 hours).5 A 
common definition is the following: SE persisting despite 
treatment with at least one benzodiazepine and at least 
one non-benzodiazepine AED.6 Each type of SE is funda-
mentally related to a specific type of short-duration sei-
zure.7 While short-duration seizures do not meet the 
definition of SE, non-SE seizures that frequently occur 
despite adequate AED treatment may actually need the 
same treatment as their SE counterparts. We arbitrarily 
define refractory seizures (RS) as frequently recurring 
(>10 episodes over 24 hours) short-duration (<t
1
) sei-
zures that cannot be controlled with at least one benzodi-
azepine and at least one non-benzodiazepine AED (same 
criteria for RSE).
RS or status epilepticus (RS/SE) is a major challenge in 
the inpatient setting for a number of reasons. First, there is 
no incontrovertible evidence in humans that all forms of 
sustained epileptiform activity in the electroencephalo-
gram (EEG) will result in clinically significant brain injury 
and enduring functional impairment in addition to that 
which has been caused by the primary brain lesion, sys-
temic disturbances, and medical interventions.8-10 Second, 
the physiological basis and pathological implications of 
various scalp EEG patterns remain controversial and it is 
not always easy to decide where some EEG patterns would 
lie in the ictal-interictal continuum.11-13 Third, it is not 
always possible to abort RS/SE with currently available 
AEDs even when several drugs are combined and adminis-
tered at maximum (nonanesthetic) doses.14,15 Fourth, 
aggressive treatment of RS/SE with general anesthesia, 
intubation, and intensive care unit (ICU) monitoring 
exposes the patient to the risk of medical complications, 
increases the cost of health care, and puts a strain on lim-
ited hospital resources.16,17 In the United States, patients 
with RS/SE are often managed in the ICU where continu-
ous EEG (CEEG) monitoring is performed.
SE, notably CSE, is an emergency that must be aborted 
immediately when encountered in the field, clinic, ambu-
lance, emergency room (ER), or inpatient setting. CSE can 
be diagnosed clinically whereas NCSE requires EEG con-
firmation. Because SE can be difficult to abort, physicians 
who are faced with this challenge must be aware of a few 
caveats. While it is well known that inducing SE in labora-
tory animals can cause irreversible brain injury, the results 
of most animal studies cannot be extrapolated to human SE, 
particularly NCSE.18-20 Several clinical studies have corre-
lated SE with increased probability of unfavorable func-
tional outcome or death. However, the increase in morbidity 
Table 1. Classification of Status Epilepticusa.
A. With Prominent Motor Symptoms B. Without Prominent Motor Symptoms (ie, Nonconvulsive SE, NCSE)
A.1. Convulsive SE (CSE, synonym: tonic-clonic SE)
 A.1.a. Generalized convulsive
 A.1.b. Focal onset evolving into bilateral convulsive SE
 A.1.c. Unknown whether focal or generalized
A.2. Myoclonic SE (prominent epileptic myoclonic jerks)
 A.2.a. With coma
 A.2.b. Without coma
A.3. Focal motor
 A.3.a. Repeated focal motor seizures (Jacksonian)
 A.3.b. Epilepsia partialis continua (EPC)
 A.3.c. Adversive status
 A.3.d. Oculoclonic status
 A.3.e. Ictal paresis (ie, focal inhibitory SE)
A.4. Tonic status
A.5. Hyperkinetic SE
B.1. NCSE with coma (including so-called “subtle” SE)
B.2. NCSE without coma
 B.2.a. Generalized
  B.2.a.a. Typical absence status
  B.2.a.b. Atypical absence status
  B.2.a.c. Myoclonic absence status
 B.2.b. Focal
  B.2.b.a.  Without impairment of consciousness (aura continua, with 
autonomic, sensory, visual, olfactory, gustatory, emotional/
psychic/experiential, or auditory symptoms)
  B.2.b.b. Aphasic status
  B.2.b.c. With impaired consciousness
 B.2.c. Unknown whether focal or generalized
  B.2.c.a. Autonomic SE
Abbreviations: SE, status epilepticus; NCSE, nonconvulsive SE; CSE, convulsive SE; EPC, epilepsia partialis continua.
aThe table shows axis 1 of the classification of SE as proposed by the International League against Epilepsy Task Force on Classification of SE and published 
in 2015 (see: Epilepsia. 2015;56:1515-1523).1 Adapted with permission.
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or mortality rate can also be attributed to other factors, 
including the etiology of SE, the age of the patient, the 
patient’s overall state at presentation (coma and GCSE are 
predictors of poor outcome), and the length of ICU treat-
ment.21-23 There is also no solid evidence that rapid termi-
nation of NCSE can affect prognosis independent of the 
effects of etiology and other factors mentioned above.24,25 
One might argue that these uncertainties justify aggressive 
treatment of RS/SE in the ICU, but intubation, anesthesia, 
and other ICU interventions may be related to an even 
higher risk of complications and mortality than SE itself, 
especially NCSE.16,17,26,27
Abortive treatment of RS/SE in the inpatient setting can 
be divided into 3 treatment lines: first-line treatment employs 
fast-acting benzodiazepines, second-line treatment involves 
the administration of intravenous (IV) AEDs, and third-line 
treatment is carried out in the ICU with general anesthetics.28 
Only the first-line treatment of CSE is currently supported by 
a high level of evidence.29 The optimal treatment for RS/SE 
and the sequence of administration of AEDs and anesthetic 
agents, especially in patients with NCSE, remains controver-
sial.30 Despite the first 2 treatment lines, about a third of SE 
patients continue seizing and progress to refractory SE and 
about half of patients with refractory SE progress to super-
refractory SE.31 This motivated experts to try drugs with no 
SE indication (eg, other AEDs or anesthetics, magnesium, 
corticosteroids, and sex hormones) and other measures, such 
as hypothermia, electroconvulsive therapy, transcranial mag-
netic stimulation, and resective surgery.32 Of these therapeu-
tic options, adding an anti-inflammatory steroid appears to 
be the most practical and most promising approach for now. 
In the last decade, nearly 2 dozen applications of anti-inflam-
matory steroids (dexamethasone or methylprednisolone) in 
our Epilepsy Center resulted in RS/SE abortion after failure 
of conventional inpatient RS/SE treatment protocols. Our 
recent (within the last 24 months) successful abortive experi-
ences with 4 adult RS/SE patients who received IV dexa-
methasone are presented here.
Case Series
All 4 patients were seen in consultation by our adult neurol-
ogy inpatient service and all had RS/SE that was controlled 
with IV dexamethasone after failure of first- and second-line 
treatment of SE. Institutional review board review of a proj-
ect summary resulted in an exemption status from institu-
tional review board approval and continued monitoring. 
Demographic and clinical information are summarized in 
Table 2. Detailed clinical information and timelines are pre-
sented in the text for each patient. SE types, seizure types, 
and EEG findings are described based on the ILAE and 
ACNS recommended nomenclatures.1-3
Patient 1 is a 61-year-old female with mesial temporal 
lobe epilepsy and bilateral hippocampal sclerosis who pre-
sented with a 3-day history of delirium. She arrived in the 
ER mildly confused with constant eye blinking. EEG 
revealed generalized 2 to 3 Hz semirhythmic delta activity 
superimposed on rhythmic theta and alpha activity with 
eye blink artifacts occurring at a rate of ~1/s (Figure 1: 
top). The findings were consistent with NCSE without 
coma with impaired consciousness (SE:B2bc; Table 1) and 
with oculoclonic status (SE:A3d; Table 1). After treatment 
with lorazepam 4-mg IV and levetiracetam 2000-mg IV, 
she was admitted to the ICU and CEEG was started. 
Oculoclonic status ceased but NCSE persisted on leveti-
racetam 1500-mg IV q12. Lacosamide 300-mg IV was 
loaded the next day followed by 200-mg IV q12. On day 3, 
valproate 2000-mg IV was also loaded followed by 1000-
mg IV q12h, but this was stopped 2 days later because of 
hyperammonemia. On day 4, the dose of levetiracetam was 
increased to 2000-mg IV q12h. She developed third-degree 
atrioventricular block and symptomatic bradycardia, which 
resolved when the dose of lacosamide was reduced to 100-
mg IV q12h. Despite all these measures, NCSE persisted 
but third-line treatment with anesthesia was not justified 
since she remained awake and conversant (albeit con-
fused). Instead, dexamethasone was started on day 5. A 
10-mg IV load was administered followed by 5.2-mg IV 
q6h. Three days after starting dexamethasone, CEEG 
showed complete resolution of epileptiform activity 
(Figure 1: bottom); and her mental status also started to 
normalize. Dexamethasone was continued for 2 more days 
at a lower dose of 5.2-mg IV q12h before it was finally 
discontinued. She remained on levetiracetam and lacos-
amide with no seizure recurrence.
Patient 2 is a 56-year-old female with a recent history of 
seizures attributed to left frontal hemorrhage from head 
trauma 2 months prior to admission. She was taking leve-
tiracetam 1000-mg PO q12h. She was found unresponsive 
and brought to the ER where she had a 60-second episode 
of focal to bilateral tonic-clonic seizure. Initial treatment 
consisted of lorazepam 4-mg IV and levetiracetam 1500-
mg IV loading dose followed by 500-mg IV q12h. EEG on 
day 2 showed left frontal interictal sharp waves. Her men-
tal status improved and she became less somnolent. She 
was seizure-free for 4 days before she had a 30-second 
focal clonic seizure involving the right face and hand with 
impaired awareness. She became inattentive and somno-
lent again so levetiracetam was increased to 1000-mg IV 
q12h. On day 5, she started having continuous right face 
and hand jerking and EEG showed 0.5 to 1/s lateralized 
periodic discharges (sharp waves) over the left hemisphere 
that were time-locked to the jerks (Figure 2: top). The find-
ings were consistent with epilepsia partialis continua 
(EPC; SE:A3b; Table 1). Brain MRI revealed acute left 
temporoparietal infarction in addition to old traumatic 
brain lesions. After lacosamide 100-mg IV q12h was 
added, myoclonic jerks stopped and she became more 
alert. On day 9, she started having focal aware clonic sei-
zures, which resembled the initial EPC except for lack of 
4 Journal of Investigative Medicine High Impact Case Reports
persistence (t
1
 < 30 seconds). The dose of lacosamide was 
increased to 150-mg IV q12h, but focal clonic seizures 
continued to occur frequently (~1/hour). Dexamethasone 
10-mg IV was loaded followed by 4-mg IV q6h. After 3 
days on dexamethasone, she became seizure-free (Figure 2: 
bottom). Dexamethasone was discontinued 25 hours after 
the last seizure. She remained seizure-free on levetirace-
tam and lacosamide.
Patient 3 is a 51-year-old male with a history of right 
frontal and parietal hemorrhage due to head trauma 6 
months prior to admission. He had seizures in the past and 
was recently admitted due to tonic-clonic seizures, which 
was controlled with levetiracetam, lacosamide, and carba-
mazepine. He was discharged on these 3 AEDs, but only 
took levetiracetam 1000-mg PO q12h prior at home. He 
started exhibiting left face, arm, and leg jerking at home. 
On admission, EEG showed 0.5 to 1/s periodic sharp and 
delta waves superimposed on irregular slow waves over 
the right hemisphere with maximum voltage over the right 
frontocentral region (Figure 3: top). The discharges were 
time-locked to the left face, arm, and leg jerks consistent 
with EPC (SE:A3b; Table 1). To abort EPC, the dose of 
levetiracetam was increased to 2000-mg IV q12h and 
lacosamide was started at a dose of 200-mg IV q12h. Left 
face and arm jerking stopped, but EPC persisted with jerk-
ing restricted to the left leg. Dexamethasone was started at 
4-mg IV q6h (loading dose was not given). Seizures 
stopped completely 3 days after initiating dexamethasone 
(Figure 3: bottom). Dexamethasone was discontinued the 
next day and she remained seizure-free on levetiracetam 
and lacosamide.
Patient 4 is a 75-year-old female with a history of meta-
static breast cancer who presented in stupor with intermittent 
60-second episodes of right lower extremity jerking. EEG 
showed 0.5 to 1/s lateralized (left > right) periodic dis-
charges with sharp morphology and superimposed semi-
rhythmic delta activity (Figure 4: top). The findings were 
consistent with NCSE without coma with impaired con-
sciousness (SE:B2bc; Table 1) with recurrent focal clonic 
seizures (t1 30-60 seconds). She was intubated for airway 
protection and propofol was started at 10-µg/kg/min IV. She 
was also loaded with 1500-mg IV of levetiracetam followed 
by 1000-mg IV q12h. Brain MRI was normal. In the ICU, 
she continued to have focal clonic seizures (1-2/hour) and 
CEEG showed persistent NCSE. Fosphenytoin 2000-mg IV 
was loaded followed by 150-mg IV q8h. Propofol was 







of the Brain and 
Relevant PAST Medical 
Conditions
Refractory Seizures or 
Status Subtypesb and 
Response to Conventional 
Therapy (A, Aborted;  
P, Persisted)
Conventional Hospital 





Time of Seizure 
Abortion With 
Dexamethasone
1, 61/female Temporal lobe epilepsy 
with bilateral mesial 
temporal sclerosis
Nonconvulsive status 





10 mg loading dose 3 days after the 
first dose of 
dexamethasone
 Oculoclonic status (A) 5.2 mg q6h (3 days)  
 5.2 mg q6h (2 days)  
2, 56/female H/o traumatic brain 
injury: left frontal 
parenchymal and 
subdural hemorrhage





10 mg loading dose 3 days after the 
first dose of 
dexamethasone
 Refractory focal clonic 
seizures (P)
4 mg q6h (3 days)  
3, 51/male H/o traumatic brain 
injury: right frontal and 
parietal hemorrhage





No loading dose 3 days after the 
first dose of 
dexamethasone
 4 mg q6h (3 days)  
4, 75/female H/o breast cancer: 
no MRI evidence of 
structural brain lesion
Nonconvulsive status 






10 mg loading dose 4 days after the 
first dose of 
dexamethasone
 Refractory focal clonic 
seizures (P)
4 mg q6h (6 days)  
aWe arbitrarily defined refractory seizures as frequently-recurring (>10 episodes over 24 hours) short-duration (<t
1
) seizures that cannot be controlled 
with at least one benzodiazepine and at least one non-benzodiazepine antiepileptic drug. Seizures that were immediately aborted are not included in the 
table.
bSee Report of the ILAE Task Force on Classification of Status Epilepticus (Epilepsia, 2015)1 and ILAE 2017 operational classification of seizure types 
(Epilepsia, 2017)2.
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Figure 1. EEG of Patient 1. Top: generalized 2 to 3 Hz semirhythmic delta activity superimposed on rhythmic theta and alpha activity 
with patient delirious and perseverating consistent with NCSE and with patient blinking every second on average (see eye blink artifacts) 
consistent with oculoclonic status. Bottom: electrographic (and clinical as seen on video) resolution of status epilepticus 3 days after 
dexamethasone was added to conventional inpatient antiepileptic therapy. Display parameters: longitudinal bipolar montage (from top to 
bottom: left-mid-right-ECG), digital filter bandpass of 1 to 70 Hz, and 60-Hz notch filter turned on; voltage-time scale is included in the 
tracing.
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Figure 2. EEG of Patient 2. Top: lateralized periodic discharges (sharp delta waves) over the left hemisphere time-locked to the 
myoclonic jerks of the right hand and face (surface EMG recorded over right face) consistent with epilepsia partialis continua. Note 
fluctuation of discharge rate from 1.5 to 2/s to 0.5 to 1/s. Bottom: electrographic resolution of periodic discharges 3 days after 
dexamethasone was added to conventional antiepileptic therapy coinciding with complete control of clinical seizures. Display parameters: 
longitudinal bipolar montage (from top to bottom: left-mid-right-EMG/ECG), digital filter bandpass of 1 to 70 Hz, and 60-Hz notch filter 
turned on; voltage-time scale is included in the tracing.
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Figure 3. EEG of Patient 3. Top: 0.5 to 1/s lateralized periodic discharges (sharp/delta waves) with maximum voltage over the right 
frontocentral superimposed on irregular slow waves and time-locked to the myoclonic jerks of the left face, arm, and leg consistent 
with epilepsia partialis continua. Bottom: electrographic (and clinical as seen on video) resolution of epilepsia partialis continua 3 
days after dexamethasone was added to conventional antiepileptic regimen. Display parameters: longitudinal bipolar montage (from 
top to bottom: left-mid-right-ECG), digital filter bandpass of 1 to70 Hz, and 60-Hz notch filter turned on; voltage-time scale is 
included in the tracing.
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Figure 4. EEG of Patient 4. Top: 1 to 2/s lateralized (left > right) periodic discharges with sharp morphology and superimposed on 
semirhythmic delta activity recorded while the patient was stuporous with intermittent episodes of right lower extremity jerking 
findings that are consistent with NCSE without coma with impaired consciousness and focal clonic seizure. Bottom: Persistence of left 
frontocentral 0.3 to 0.5/s periodic discharges approximately 5 days after dexamethasone was added and the patient was already seizure-
free. Display parameters: longitudinal bipolar montage (from top to bottom: left-mid-right-ECG), digital filter bandpass of 1 to 70 Hz, and 
60-Hz notch filter turned on; voltage-time scale is included in the tracing.
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uptitrated but she became hypotensive at 40 µg/kg/min. 
Midazolam drip was started and burst suppression was sus-
tained for 2 days with 60 to 80 mg/kg/min of IV midazolam. 
Every time midazolam was weaned off, epileptiform dis-
charges reappeared. Lacosamide 750-mg IV q12h IV was 
added. CEEG showed persistent NCSE with periodic sharp 
waves appearing more localized over the left frontocentral 
region. Focal clonic seizures also started to involve the right 
face and arm in addition to the leg. On day 6, dexamethasone 
10-mg IV was loaded followed by 4-mg IV q6h. Four days 
after dexamethasone was started, all clinical seizures stopped 
but 0.3 to 0.5/s lateralized periodic discharges persisted in 
EEG (Figure 4: bottom). Dexamethasone was continued for 
2 more days after she stopped seizing. She remained seizure-
free on levetiracetam, lacosamide, and phenytoin.
Discussion
Seizure control can be achieved by eliminating all factors that 
promote neuronal hyperexcitability and hypersynchrony. In 
practice, this is not always feasible in the acutely ill patient. In 
the inpatient setting, the general approach is to abort seizures 
immediately with rapidly acting AEDs, followed by mainte-
nance therapy to prevent seizure recurrence. Unfortunately, 
RS/SE—seizures that persist despite conventional treatment 
with maximal doses of multiple AEDs—is not uncommon in 
the inpatient setting. Our case series shows that adding IV 
dexamethasone to conventional antiseizure therapy (loraze-
pam, levetiracetam, lacosamide, valproate, fosphenytoin, 
and/or anesthetic agents) can help abort RS/SE. Clinical and 
electrographic seizures stopped in all 4 patients 3 to 4 days 
after dexamethasone was started, and all patients remained 
seizure-free on 2 or 3 AEDs after dexamethasone was discon-
tinued 1 to 3 days after all seizures stopped.
Inflammation plays an important role in seizure disor-
ders. This role can be viewed from the perspective of auto-
immunity, epilepsy, and pharmacoresistant seizures. The 
link between autoimmunity and seizure disorders is obvious 
in the case of autoimmune encephalitis where autoantibod-
ies target biomolecules involved in neuronal signaling.33 
However, even if autoimmunity is not the primary mecha-
nism causing the seizure disorder, inflammation and immune 
processes may still be important in the pathogenesis of epi-
lepsy.34,35 There is mounting evidence that inflammatory 
mediators released from the brain and peripheral immune 
cells may be involved in generating seizures (ictogenesis) 
and emergence of epileptic networks (epileptogenesis).36,37 
Finally, it is known that some inflammatory mediators play 
a role, not only in generating but also in maintaining sei-
zures, implying that these inflammatory mediators contrib-
ute to the pharmacoresistance of RS/SE.
Animal research has shown that anti-inflammatory ther-
apy given during or shortly after SE reduces the severity of 
the ensuing epilepsy, as reflected by a reduction in the inci-
dence, frequency, severity, and spread of seizures and by a 
decrease in brain cell loss and comorbidities.32 Nonetheless, 
we will emphasize animal experiment results indicating 
that brain inflammation occurs during SE and plays a role 
in driving seizures. Inflammatory mediators can lower the 
seizure threshold in animals by acting on neuronal recep-
tors altering membrane excitability or by acting on genes 
inducing the transcription of proteins involved in synaptic 
plasticity.38,39 In rodents, various inflammatory response 
molecules or signaling pathways, such as the interleukins 
IL-1β and IL-1R1, toll-like receptor-4 (TLR4), cyclooxy-
genase-2 (COX-2) and prostaglandins, and complement, 
contribute to the onset and recurrence of stimulus-pro-
voked seizures.40-42 Manipulation of some of these inflam-
matory pathways may reduce the incidence and recurrence 
of SE.32 For example, IL-1 receptor antagonists reduced 
the incidence, delayed the onset, and shortened the dura-
tion of pilocarpine-induced SE.43 Anakinra, a specific IL-1 
receptor antagonist used to treat rheumatoid arthritis, 
caused a transient decrease in spike frequency when 
injected 3 hours after electrically induced SE.44 Antagonists 
of the P2X7 receptor in immune and other cells reduced 
the duration of acute SE.45 In an animal model of pharma-
coresistant SE, co-administration of P2X7 receptor antag-
onists and benzodiazepines suppressed SE, presumably by 
reducing microglia activation and IL-1β levels in the fore-
brain.46 Injecting dexamethasone prior to pilocarpine in 
rats reduced the number of rats developing SE and, in rats 
that developed SE, the onset of SE was delayed and mor-
tality was prevented; blood-brain barrier damage was also 
significantly reduced by dexamethasone.47 These results 
support our choice of dexamethasone (Decadron) over 
methylprednisolone (Solu-Medrol). In reality, we tend to 
choose dexamethasone for patients with no underlying 
autoimmunity since this drug is familiar to most physi-
cians involved in the care of patients with RS/SE. There 
are, however, differences between dexamethasone, meth-
ylprednisolone, and other corticosteroids that physicians 
might have to consider when using anti-inflammatory ste-
roids as adjunctive therapy for seizures.48
Human RS/SE is most likely influenced by inflamma-
tory mediators, but few studies directly address this issue. 
Extensive extravasation of albumin has been detected in 
patients who died during SE indicating disruption of the 
blood-brain barrier.49 Signs of pronounced focal inflamma-
tion, including strong IL-1β expression, intense gliosis, 
and minimal lymphocytic infiltration, were found in the 
temporal cortex resected from a patient with refractory 
SE.50 The endogenous control of brain inflammation may 
be inadequate during SE.32 Children with febrile SE have 
elevated serum levels of IL-1β and IL-6; and children with 
febrile SE have higher HMGB1 levels as well compared 
with controls with fever but no seizures.51 The cerebrospi-
nal fluid levels of the cytokines IL-6, IL-8, and CXCL10 
were much higher in patients with refractory SE due to 
febrile infection-related epilepsy syndromes than in 
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patients with other inflammatory brain disorders.52 The 
fact that adrenocorticotropic hormone (ACTH) and pred-
nisolone are effective in West syndrome imply that inflam-
matory mechanisms are important in the pathophysiology 
of infantile spasm.53
Epilepsy pharmacotherapy relies heavily on seizure pre-
vention with AEDs, but this approach should not be exclu-
sive. An understanding of the mechanisms in which 
inflammatory mediators promote the formation of epileptic 
circuitry can lead to novel therapies for suppressing epilep-
togenesis directly.54-56 A related issue in need of urgent 
attention is the current approach to RS/SE in the inpatient 
setting. Immunotherapies, such as corticosteroids, plasma 
exchange, intravenous immunoglobulins, rituximab, and 
cyclophosphamide, are, by and large, reserved for seizure 
disorders with underlying autoimmune mechanisms.57,58 
The use of immunomodulators to control RS/SE in the typi-
cal seizure patient with no autoimmune disorder deserves 
investigation. Controlled studies must be conducted to 
determine whether broad-spectrum anti-inflammatory ste-
roids, such as dexamethasone or methylprednisolone, can 
help abort RS/SE and obviate intubation and anesthesia. The 
case series presented here only provides anecdotal evidence 
for stimulating discussion and perhaps further experimental 
investigations. These patients were treated based on their 
presenting and persistent situations, not in the systematic 
way required for scientific evidence.
Conclusion
Despite an increase in the availability of fast-acting AEDs 
and anesthetic agents, aborting RS/SE in the inpatient set-
ting can still be challenging. Multiple AEDs administered 
at maximal doses can fail to abort RS/SE. Because stan-
dard AED regimens may fail to abort RS/SE, and because 
intubation and anesthesia are not without risks, clinicians 
must have other options to treat RS/SE. Our case series 
shows that anti-inflammatory agents, in particular dexa-
methasone, may satisfy this need. Furthermore, our case 
series suggests a key role for inflammatory or immune fac-
tors in generating and perpetuating seizures, or at least 
drug-resistant seizures, in humans.
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